|
1
|
Hanon O, Paillaud E, Baudin A, Chaoui S, Canovas J, Iratni L, Lucas P, Mabungu H, Villebrun M, Chambraud C, Rollot-Trad F, Bringuier M, Broussier A, Spiess N, Elalamy I, Canouï-Poitrine F. 1590P Interest of preventive treatment with anticoagulant in older patients with cancer on venous thrombo-embolic events (ANTIGONE study): Design and baseline results. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
|
2
|
Boudou-Rouquette P, de Moura A, Martinez-Tapia C, Serrano AG, Chahwakilian A, Jouinot A, Ulmann G, Orvoën G, Chambraud C, Durand JP, Caillet P, Goldwasser F, Paillaud E, Canouï-Poitrine F, Aregui A, Baronn M, Bringuier M, Bouvard E, Caillet P, Cosqueric G, Corsin L, Cudennec T, Chahwakilian A, Djender A, Dupuydupin E, Ebadi N, Fossey-Diaz V, Gisselbrecht M, Goldstein C, Gonzalez B, Laurent M, Leguen J, Lefevre M, Lazarovici-Nagera C, Lorisson E, Massias J, Mebarki S, Orvoen G, Pamoukdjian F, Scain AL, de Lempdes GR, Rollot-Trad F, Varnier G, Vincent H, Paillaud E, Raynaud-Simon A, Boudou-Rouquette P, Brain E, Culine S, Frelaut M, Ghebriou D, Gligorov J, Lopez-Trabada-Ataz SHD, Mir O, Tournigand C, Aparicio T, Touboul C, Lagrange JL, Benyahia S, Bonhomme S, Mota A, Philocles G, Ouakinine C, Audureau E, Bastuji-Garin S, Canouï-Poitrine F, Loriot MA, Natella PA, Martinez-Tapia C, Reinald N, Rello S, Lafage M, Allain M, Chambraud C, Baudin A, Bobin M, Canovas J, Chaoui S, Iratni L, Garrigou S, Lacour S, Mabungu H, Morisset L, Saadaoui B. Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. Clin Nutr 2022; 41:1073-1082. [DOI: 10.1016/j.clnu.2022.02.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 01/15/2022] [Accepted: 02/16/2022] [Indexed: 12/31/2022]
|
|
3
|
Fagherazzi G, Chambraud C, Dow C, Mancini FR, Affret A, Balkau B, Magliano DJ, Boutron-Ruault MC, Bonnet F. What are the determinants of a concerned vision of the future when living with type 2 diabetes? Results from the E3N-AfterDiab study. Chronic Illn 2019; 15:236-241. [PMID: 30282463 DOI: 10.1177/1742395318801934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives Identification of characteristics associated with a negative experience with type 2 diabetes may help to develop novel intervention to improve the outlook of people with the disease. Our aim was to identify determinants of a self-reported concerned vision about the future when living with type 2 diabetes. Methods In 2630 women with type 2 diabetes from the E3N-AfterDiab study, we used multivariable logistic regression models to derive odds-ratios and 95% confidence intervals. Results Women with elevated HbA1c levels (OR = 2.42 (1.67–3.49) for ≥7.2% when compared to <6.2%), or treated with injected glucose lowering treatments (OR = 1.37 [1.05–1.81]) had a higher risk of a concerned vision of the future. Age and obesity were associated with a decreased risk. Hypertension, duration of diabetes, smoking, fasting glucose levels, and years of education were not associated with a concerned vision of the future. Discussion Our findings highlight the importance of both glycemic control and the type of treatment on the perception of the future when living with type 2 diabetes. Subgroups of patients based on these characteristics may receive a specific attention from healthcare professionals to address potential concerns related with diabetes management or the fear of complications.
Collapse
Affiliation(s)
- Guy Fagherazzi
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France
| | - Clélia Chambraud
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France
| | - Courtney Dow
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France
| | - Francesca Romana Mancini
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France
| | - Aurélie Affret
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France
| | - Beverley Balkau
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France.,3 University Versailles, Saint Quentin, University Paris-Sud, Villejuif, France
| | - Dianna J Magliano
- 4 Baker IDI, Clinical Diabetes and Epidemiology Laboratory, Melbourne, Australia
| | - Marie-Christine Boutron-Ruault
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France
| | - Fabrice Bonnet
- 1 INSERM U1018, Gustave Roussy Institute, CESP, Villejuif, France.,2 University Paris-Saclay, University Paris-Sud, Villejuif, France.,5 CHU Rennes, Rennes 1 University, France
| |
Collapse
|